APPLIED FILTERS:
Cytiva and Testa Center are inviting scientific companies and researchers to compete in the 2024 Testa Challenge. Winners have the opportunity to accelerate their innovations around the scale up and manufacturing of antibody (Ab) intermediates, as it relates to Ab-drug conjugates (ADCs).
Read MoreCytiva is among the top one percent of companies to receive the prestigious platinum ranking from EcoVadis, a leading provider of business sustainability performance rankings.
Read MoreRecognizing the long-term needs of the biopharma industry in China and Asia-Pacific, global life sciences leader Cytiva has opened its expanded Shanghai facility.
Read MoreCytiva and LevitasBio join forces to transform single-cell workflow.
Read MoreCytiva and RoosterBio collaborate to improve the exosome purification process currently slowing adoption of promising gene therapies and other new modalities.
Read MoreCollaboration will boost capabilities to deliver cancer treatment within Thailand and to Southeast Asia by 2025
Read MoreCytiva introduces the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant protein purification. The self-cleaving traceless tag and complementary affinity chromatography resin standardizes purification for any protein, rendering it unnecessary to use specific affinity binding partners for each protein.
Read MoreThe manufacturing facility in Pune will double Cytiva’s manufacturing capacity in India and the Experience Center will provide critical training programs to accelerate the development of novel therapeutics.
Read MoreCytiva launches the NanoAssemblr commercial formulation system for lipid nanoparticle medicines. It offers end-to-end manufacturing from clinical development to commercial production, using scalable mixing technology.
Read MoreOn May 1 the biotechnology, laboratory and medical businesses of Pall Corporation became part of Cytiva. You'll now find the same great Pall products and content hosted here.